| Autor: |
Cavo, M. San-Miguel, J. Usmani, S.Z. Weisel, K. Dimopoulos, M.A. Avet-Loiseau, H. Paiva, B. Bahlis, N.J. Plesner, T. Hungria, V. Moreau, P. Mateos, M.-V. Perrot, A. Iida, S. Facon, T. Kumar, S. van de Donk, N.W.C.J. Sonneveld, P. Spencer, A. Krevvata, M. Heuck, C. Wang, J. Ukropec, J. Kobos, R. Sun, S. Qi, M. Munshi, N. |
| Jazyk: |
angličtina |
| Rok vydání: |
2022 |
| Předmět: |
|
| Popis: |
We explored minimal residual disease (MRD) in relapsed/refractory multiple myeloma (RRMM) and transplant-ineligible (TIE) newly diagnosed multiple myeloma (NDMM) using data from 4 phase 3 studies (POLLUX, CASTOR, ALCYONE, and MAIA). Each study previously demonstrated that daratumumab-based therapies improved MRD negativity rates and reduced the risk of disease progression or death by approximately half vs standards of care. We conducted a large-scale pooled analysis for associations between patients achieving complete response or better (≥CR) with MRD-negative status and progression-free survival (PFS). MRD was assessed via next-generation sequencing (10−5 sensitivity threshold). Patient-level data were pooled from all 4 studies and for patients with TIE NDMM and patients with RRMM who received ≤2 prior lines of therapy (≤2 PL). PFS was evaluated by response and MRD status. Median follow-up (months) was 54.8 for POLLUX, 50.2 for CASTOR, 40.1 for ALCYONE, and 36.4 for MAIA. Patients who achieved ≥CR and MRD negativity had improved PFS vs those who failed to reach CR or were MRD positive (TIE NDMM and RRMM hazard ratio [HR] 0.20, P |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
